 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||||||||| midazolam/ketamine sublingual tablet (MELT-300) / Melt Pharma
New P3 trial: A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR) (clinicaltrials.gov) - Apr 25, 2024
P3, N=486, Not yet recruiting, Sponsor: Melt Pharmaceuticals
- |||| midazolam/ketamine sublingual tablet (MELT-300) / Melt Pharma
Trial completion: A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR) (clinicaltrials.gov) - Dec 19, 2022
P2, N=338, Completed, Sponsor: Melt Pharmaceuticals
Recruiting --> Completed
- || midazolam/ketamine sublingual tablet (MELT-300) / Melt Pharma
Trial completion date, Trial primary completion date: A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR) (clinicaltrials.gov) - Aug 25, 2022
P2, N=300, Recruiting, Sponsor: Melt Pharmaceuticals
Recruiting --> Completed Trial completion date: May 2022 --> Oct 2022 | Trial primary completion date: Mar 2022 --> Sep 2022
- |||| midazolam/ketamine sublingual tablet (MELT-300) / Melt Pharma
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR) (clinicaltrials.gov) - Jan 11, 2022
P2, N=300, Recruiting, Sponsor: Melt Pharmaceuticals
Trial completion date: May 2022 --> Oct 2022 | Trial primary completion date: Mar 2022 --> Sep 2022 Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> May 2022 | Initiation date: Nov 2021 --> Jul 2021 | Trial primary completion date: Dec 2021 --> Mar 2022
- ||||| midazolam/ketamine sublingual tablet (MELT-300) / Melt Pharma
New P2 trial: A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR) (clinicaltrials.gov) - Nov 24, 2021
P2, N=300, Not yet recruiting, Sponsor: Melt Pharmaceuticals
- || midazolam/ketamine sublingual tablet (MELT-300) / Melt Pharma
Trial completion: Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine (clinicaltrials.gov) - Feb 22, 2021
P1, N=17, Completed, Sponsor: Melt Pharmaceuticals
Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> May 2022 | Initiation date: Nov 2021 --> Jul 2021 | Trial primary completion date: Dec 2021 --> Mar 2022 Not yet recruiting --> Completed
- || midazolam/ketamine sublingual tablet (MELT-300) / Melt Pharma
New P1 trial: Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine (clinicaltrials.gov) - Feb 22, 2021
P1, N=25, Completed, Sponsor: Melt Pharmaceuticals
- | midazolam/ketamine sublingual tablet (MELT-300) / Melt Pharma
New P1 trial: Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine (clinicaltrials.gov) - Jul 23, 2020
P1, N=18, Not yet recruiting, Sponsor: Melt Pharmaceuticals